You are here

  • Home
  • Archive
  • Volume 2, Issue Suppl 3
  • A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes

Article Text

Article menu

Download PDFPDF

Poster Presentation
A randomized pilot trial evaluating safety and immunogenicity of recMAGE-A3 + AS15 immunotherapeutic administered by intramuscular versus intradermal/subcutaneous routes
  1. Craig L Slingluff1,
  2. Gina R Petroni1,
  3. Walter C Olson1,
  4. Kimberly A Chianese-bullock1,
  5. Kelly T Smith1,
  6. Mark E Smolkin1,
  7. Nadedja Galeassi1,
  8. William Grosh1,
  9. Geoffrey Weiss1,
  10. Kristy Scott1 and
  11. Ana Hornillo2
  1. Aff1 grid.27755.32000000009136933XUniversity of Virginia Charlottesville USA
  2. Aff2 Glaxo Smith Kline Belgium

https://doi.org/10.1186/2051-1426-2-S3-P60

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Introduction

    The recMAGE-A3 protein has been administered intramuscularly (IM) with immunostimulant AS15 as an experimental immunotherapeutic. AS15 contains 3-O-desacyl-4'-monophosphoryl lipid A (MPL), QS-21, CpG 7909 and liposome. This MAGE-A3/AS15 immunotherapeutic has not been studied for intradermal (ID) or subcutaneous (SC) use. A clinical trial (NCT01425749) was initiated to test the hypotheses that ID/SQ administration is safe and may induce CD4+ and CD8+ T cell responses to MAGE-A3.

    Patients and methods

    Twenty-five eligible patients with resected stage IIB-IV MAGE-A3+ melanoma were randomized to 2 arms, treated with MAGE-A3/AS15 Immunotherapeutic IM (Arm A, n = 13) or ID/SC (Arm B, n = 12). Adverse events (CTCAE 4) were recorded. Antibody (Ab) responses to MAGE-A3 protein were assessed by ELISA assay. T cell responses were assessed by flow cytometry after intracellular cytokine staining (ICS) for multifunctional CD4+ and CD8+ responses to overlapping MAGE-A3 peptides, assaying lymphocytes from peripheral blood (PBMC) and sentinel immunized node (SIN), after one in vitro stimulation.

    Results

    In both arms, the recMAGE-A3/AS15 immunotherapeutic was well-tolerated, with only one grade 3 treatment-related adverse event (hyperglycemia, Arm B), and no grade 4 or 5 events. Grade 2 injection site reactions were observed in 10 patients in Arm A and 7 in Arm B (P > 0.3). Ab responses were detected in all patients, most with high titers persisting at least 6 months, without difference between arms. Preliminary T cell data are that multifunctional (IFNg and TNFα) CD4+ T cell responses to MAGE-A3 were detected in 64% of patients (54% A; 75% B; Table 1). Multifunctional CD8+ T cell responses were evident in 20% of patients (8% A, 33% B). CD4+ responses were higher magnitude in SIN than in PBMC.

    View this table:

    Multifunctional (IFNg and TNFα) T cell responses to MAGE-A3

    Conclusion

    Safety profiles were comparable for ID/SC and IM administration of the MAGE-A3/AS15 immunotherapeutic, which induced high-titer Ab, multifunctional CD4+ Th1 responses, and CD8+ responses when administered by either route. Immune responses were more readily detected in the SIN than in PBMC. These pilot data support further investigation of ID/SC immunization with antigen plus AS15 to support Th1 CD4+ responses and CD8+ responses. Production of Th1 cytokines IFNg and TNFα suggests the induced CD4+ responses may support CD8+ T cells. Other forms of antigen (e.g.: long peptides) may further support induction of CD8+ T cell responses in combination with AS15.

    Funding source: GlaxoSmithKline Biologicals SA